Retroviral Infections of Small Animals

Veterinary Clinics of North America - Small Animal Practice

Volumn 38, Issue 4, 2008, Pages 879-901

  Dunham, Stephen P ^a   Graham, Elizabeth ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; CELL RECEPTOR; CYTOKINE; DNA VACCINE; FELINE IMMUNODEFICIENCY VIRUS VACCINE; FELINE LEUKEMIA VIRUS VACCINE; FELINE ONCORNAVIRUS CELL MEMBRANE ANTIGEN; GAG PROTEIN; GLYCOPROTEIN GP 70; INACTIVATED VIRUS VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY; PROTEINASE; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; VIRUS ANTIBODY; VIRUS DNA; VIRUS ENVELOPE PROTEIN; VIRUS ENVELOPE PROTEIN RECEPTOR ANTAGONIST; VIRUS RNA; VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AIDS RELATED COMPLEX; ANEMIA; ANTIBODY TITER; BONE MARROW TRANSPLANTATION; CANCER CLASSIFICATION; CARCINOGENESIS; CAT DISEASE; CELLULAR IMMUNITY; CLINICAL FEATURE; DIAGNOSTIC ACCURACY; DISEASE COURSE; DOG DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG SYNTHESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FALSE POSITIVE RESULT; FELINE LEUKEMIA VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOFLUORESCENCE TEST; INFECTION RISK; LENTIVIRINAE; LIFE CYCLE; LYMPHOMA; MOLECULAR EVOLUTION; NONHUMAN; OPPORTUNISTIC INFECTION; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; RETROVIRUS; RETROVIRUS INFECTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; RNA INTERFERENCE; SENSITIVITY AND SPECIFICITY; SPUMA VIRUS; VACCINE PRODUCTION; VIREMIA; VIROGENESIS; VIRUS CHARACTERIZATION; VIRUS DETECTION; VIRUS GENOME; VIRUS ISOLATION; VIRUS MUTATION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS TRANSMISSION; VIRUS VIRULENCE;

ANIMALS; CAT DISEASES; CATS; DOG DISEASES; DOGS; FEMALE; GENOME, VIRAL; MALE; RETROVIRIDAE; RETROVIRIDAE INFECTIONS;

ANIMALIA; CANIS FAMILIARIS; FELINE IMMUNODEFICIENCY VIRUS; FELINE LEUKEMIA VIRUS;

EID: 43849085905     PISSN: 01955616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cvsm.2008.03.005     Document Type: Review

References (138)

1. Jarrett O. Strategies of retrovirus survival in the cat. Vet Microbiol 69 1-2 (1999) 99-107
2. Romen F., Pawlita M., Sehr P., et al. Antibodies against Gag are diagnostic markers for feline foamy virus infections while Env and Bet reactivity is undetectable in a substantial fraction of infected cats. Virology 345 2 (2006) 502-508
3. Roy-Burman P. Endogenous env elements: partners in generation of pathogenic feline leukemia viruses. Virus Genes 11 2-3 (1995) 147-161
4. Sykes G.P., King J.M., and Cooper B.C. Retrovirus-like particles associated with myeloproliferative disease in the dog. J Comp Pathol 95 4 (1985) 559-564
5. Modiano J.F., Getzy D.M., Akol K.G., et al. Retrovirus-like activity in an immunosuppressed dog: pathological and immunological findings. J Comp Pathol 112 2 (1995) 165-183
6. Ghernati I., Corbin A., Chabanne L., et al. Canine large granular lymphocyte leukemia and its derived cell line produce infectious retroviral particles. Vet Pathol 37 4 (2000) 310-317
7. Ghernati I., Auger C., Chabanne L., et al. Characterization of a canine long-term T cell line (DLC 01) established from a dog with Sézary syndrome and producing retroviral particles. Leukemia 13 8 (1999) 1281-1290
8. Sodora D.L., Shpaer E.G., Kitchell B.E., et al. Identification of three feline immunodeficiency virus (FIV) env gene subtypes and comparison of the FIV and human immunodeficiency virus type 1 evolutionary patterns. J Virol 68 4 (1994) 2230-2238
9. Burkhard M.J., and Dean G.A. Transmission and immunopathogenesis of FIV in cats as a model for HIV. Curr HIV Res 1 1 (2003) 15-29
10. Bachmann M.H., Mathiason-Dubard C., Learn G.H., et al. Genetic diversity of feline immunodeficiency virus: dual infection, recombination, and distinct evolutionary rates among envelope sequence clades. J Virol 71 6 (1997) 4241-4253
11. Anderson M.M., Lauring A.S., Burns C.C., et al. Identification of a cellular cofactor required for infection by feline leukemia virus. Science 287 5459 (2000) 1828-1830
12. Anderson M.M., Lauring A.S., Robertson S., et al. Feline Pit2 functions as a receptor for subgroup B feline leukemia viruses. J Virol 75 22 (2001) 10563-10572
13. Willett B.J., McMonagle E.L., Logan N., et al. Probing the interaction between feline immunodeficiency virus and CD134 by using the novel monoclonal antibody 7D6 and the CD134 (Ox40) ligand. J Virol 81 18 (2007) 9665-9679
14. Shimojima M., Miyazawa T., Ikeda Y., et al. Use of CD134 as a primary receptor by the feline immunodeficiency virus. Science 303 5661 (2004) 1192-1195
15. Willett B.J., Hosie M.J., Neil J.C., et al. Common mechanism of infection by lentiviruses. Nature 385 6617 (1997) 587
16. Takeuchi Y., Vile R.G., Simpson G., et al. Feline leukemia virus subgroup B uses the same cell surface receptor as gibbon ape leukemia virus. J Virol 66 2 (1992) 1219-1222
17. Quigley J.G., Burns C.C., Anderson M.M., et al. Cloning of the cellular receptor for feline leukemia virus subgroup C (FeLV-C), a retrovirus that induces red cell aplasia. Blood 95 3 (2000) 1093-1099
18. Tailor C.S., Willett B.J., and Kabat D. A putative cell surface receptor for anemia-inducing feline leukemia virus subgroup C is a member of a transporter superfamily. J Virol 73 8 (1999) 6500-6505
19. Mendoza R., Anderson M.M., and Overbaugh J. A putative thiamine transport protein is a receptor for feline leukemia virus subgroup A. J Virol 80 7 (2006) 3378-3385
20. Pedersen N.C. Virologic and immunologic aspects of feline infectious peritonitis virus infection. Adv Exp Med Biol 218 (1987) 529-550
21. Ishida T., Washizu T., Toriyabe K., et al. Feline immunodeficiency virus infection in cats of Japan. J Am Vet Med Assoc 194 2 (1989) 221-225
22. Yamamoto J.K., Hansen H., Ho E.W., et al. Epidemiologic and clinical aspects of feline immunodeficiency virus infection in cats from the continental United States and Canada and possible mode of transmission. J Am Vet Med Assoc 194 2 (1989) 213-220
23. O'Neil L.L., Burkhard M.J., and Hoover E.A. Frequent perinatal transmission of feline immunodeficiency virus by chronically infected cats. J Virol 70 5 (1996) 2894-2901
24. O'Neil L.L., Burkhard M.J., Diehl L.J., et al. Vertical transmission of feline immunodeficiency virus. AIDS Res Hum Retroviruses 11 1 (1995) 171-182
25. Sellon R.K., Jordan H.L., Kennedy-Stoskopf S., et al. Feline immunodeficiency virus can be experimentally transmitted via milk during acute maternal infection. J Virol 68 5 (1994) 3380-3385
26. Allison R.W., and Hoover E.A. Feline immunodeficiency virus is concentrated in milk early in lactation. AIDS Res Hum Retroviruses 19 3 (2003) 245-253
27. Callanan J.J., Thompson H., Toth S.R., et al. Clinical and pathological findings in feline immunodeficiency virus experimental infection. Vet Immunol Immunopathol 35 1-2 (1992) 3-13
28. Beatty J.A., Willett B.J., Gault E.A., et al. A longitudinal study of feline immunodeficiency virus-specific cytotoxic T lymphocytes in experimentally infected cats, using antigen-specific induction. J Virol 70 9 (1996) 6199-6206
29. Fevereiro M., Roneker C., Laufs A., et al. Characterization of two monoclonal antibodies against feline immunodeficiency virus gag gene products and their application in an assay to evaluate neutralizing antibody activity. J Gen Virol 72 Pt 3 (1991) 617-622
30. Addie D.D., Dennis J.M., Toth S., et al. Long-term impact on a closed household of pet cats of natural infection with feline coronavirus, feline leukaemia virus and feline immunodeficiency virus. Vet Rec 146 15 (2000) 419-424
31. Jarrett W.F., Martin W.B., Crighton G.W., et al. Transmission experiments with leukemia (lymphosarcoma). Nature 202 (1964) 566-567
32. Jarrett W.F., Crawford E.M., Martin W.B., et al. A virus-like particle associated with leukemia (lymphosarcoma). Nature 202 (1964) 567-569
33. Hardy W.D. Haematopoietic tumours of cats. J Am Anim Hosp Assoc 17 (1981) 921-940
34. Hofmann-Lehmann R., Huder J.B., Gruber S., et al. Feline leukaemia provirus load during the course of experimental infection and in naturally infected cats. J Gen Virol 82 (2001) 1589-1596
35. Hofmann-Lehmann R., Tandon R., Boretti F.S., et al. Reassessment of feline leukaemia virus (FeLV) vaccines with novel sensitive molecular assays. Vaccine 24 8 (2006) 1087-1094
36. Hofmann-Lehmann R., Cattori V., Tandon R., et al. Vaccination against the feline leukaemia virus: outcome and response categories and long-term follow-up. Vaccine 25 30 (2007) 5531-5539
37. Tandon R., Cattori V., Gomes-Keller M.A., et al. Quantitation of feline leukaemia virus viral and proviral loads by TaqMan(R) real-time polymerase chain reaction. J Virol Methods 130 1-2 (2005) 124-132
38. Dorn C.R., Taylor D.O., Schneider R., et al. Survey of animal neoplasms in Alameda and Contra Costa Counties, California. II. Cancer morbidity in dogs and cats from Alameda County. J Natl Cancer Inst 40 (1968) 307-318
39. Lenz J., Celander D., Crowther R.L., et al. Determination of the leukaemogenicity of a murine retrovirus by sequences within the long terminal repeat. Nature 308 5958 (1984) 467-470
40. Levy L.S., Gardner M.B., and Casey J.W. Isolation of a feline leukaemia provirus containing the oncogene myc from a feline lymphosarcoma. Nature 308 (1984) 853-856
41. Mullins J.I., Brody D.S., Binari R.C., et al. Viral transduction of c-myc gene in naturally occurring feline leukaemias. Nature 308 (1984) 856-858
42. Neil J.C., Hughes D., McFarlane R., et al. Transduction and rearrangement of the myc gene by feline leukaemia virus in naturally occurring T-cell leukaemias. Nature 308 (1984) 814-820
43. Hardy W.D. Feline oncoretroviruses. In: Levy J.A. (Ed). The Retroviridae (1993), Plenum Press, New York 109-180
44. Guillermo Couto C. What is new on feline lymphoma?. J Feline Med Surg 3 4 (2001) 171-176
45. Crighton G.W. The diagnosis of leukaemia in the cat. J Small Anim Pract 10 (1969) 571-577
46. Crighton G.W. Lymphosarcoma in the cat. Vet Rec 84 (1969) 329-331
47. Hanlon L., Argyle D., Bain D., et al. Feline leukaemia virus DNA vaccine efficiency is enhanced by coadministration with interleukin-12 (IL-12) and IL-18 expression vectors. J Virol 75 18 (2001) 8424-8433
48. Pedersen N.C. Feline leukaemia virus infection. In: Pedersen N.C. (Ed). Feline infectious diseases (1988), American Veterinary Publications, Goleta (CA) 83-106
49. Louwerens M., London C.A., Pedersen N.C., et al. Feline lymphoma in the postfeline leukemia virus era. J Vet Intern Med 19 (2005) 329-335
50. Koshy R., Wong-Staal F., Gallo R.C., et al. Distribution of feline leukaemia virus DNA sequences in tissues of normal and leukaemia domestic cats. Virology 99 (1979) 135-144
51. Koshy R., Gallo R.C., and Wong-Staal F. Characterization of the endogenous feline leukemia virus-related DNA sequences in cats and attempts to identify exogenous viral sequences in tissues of virus-negative leukemic animals. Virology 103 (1980) 434-445
52. Gabor L.J., Love D.N., Malik R., et al. Feline immunodeficiency virus status of Australian cats with lymphosarcoma. Aust Vet J 79 8 (2001) 540-545
53. Favrot C., Wilhelm S., Grest P., et al. Two cases of FeLV-associated dermatoses. Vet Dermatol 16 (2005) 407-412
54. Hardy W.D., McClelland A.J., Zuckerman E.E., et al. Development of virus non-producer lymphosarcomas in pet cats exposed to FeLV. Nature 288 (1980) 90-92
55. Mackey L., Jarrett W., Jarrett O., et al. Anemia associated with feline leukaemia virus infection in cats. J Natl Cancer Inst 54 1 (1975) 209-217
56. Hoover E.A., Kociba G.J., Hardy W.D., et al. Erythroid hypoplasia in cats inoculated with feline leukaemia virus. J Natl Cancer Inst 53 5 (1974) 1271-1276
57. Onions D., Jarrett O., Testa N., et al. Selective effect of feline leukaemia virus on early erythroid precursors. Nature 296 (1982) 156-158
58. Hoover E.A., and Mullins J.I. Feline leukaemia virus infection and disease. J Am Vet Med Assoc 199 10 (1991) 1287-1297
59. Quigley J.G., Yang Z., Worthington M.T., et al. Identification of a human heme exporter that is essential for erythropoiesis. Cell 118 6 (2004) 757-766
60. Kipar A., Kremendahl J., Grant C.K., et al. Expression of viral proteins in feline leukaemia virus-associated enteritis. Vet Pathol 37 (2000) 129-136
61. Gross T.L., Clark E.G., Hargis A.M., et al. Giant cell dermatosis in FeLV-positive cats. Vet Dermatol 4 3 (1993) 117-122
62. Jarrett O., Russell P.H., and Stewart M.F. Protection of kittens from feline leukaemia virus infection by maternally-derived antibody. Vet Rec 101 (1977) 304-305
63. Flynn J.N., Hanlon L., and Jarrett O. Feline leukaemia viruses: protective immunity is mediated by virus-specific cytotoxic T lymphocytes. Immunology 101 (2000) 1-10
64. Flynn J.N., Dunham S.P., Mueller A., et al. Involvement of cytolytic and non-cytolytic T cells in the control of feline immunodeficiency virus infection. Vet Immunol Immunopathol 85 (2002) 159-170
65. Russell P.H., and Jarrett O. The occurrence of feline leukaemia virus neutralizing antibodies in cats. Int J Cancer 22 (1978) 351-357
66. Elder J.H., McGee J.S., Munson M., et al. Localization of neutralizing regions of the envelope gene of feline leukaemia virus by using anti-synthetic peptide antibodies. J Virol 61 (1987) 8-15
67. Nick S., Klaws J., Friebel K., et al. Virus neutralizing and enhancing epitopes characterized by synthetic oligopeptides derived from the feline leukaemia virus glycoprotein sequence. J Gen Virol 71 (1990) 77-83
68. Flynn J.N., Dunham S.P., Watson V., et al. Longitudinal analysis of feline leukaemia virus-specific cytotoxic T lymphocytes: correlation with recovery from infection. J Virol 76 5 (2002) 2306-2315
69. Hoover E.A., Olsen R.G., Hardy W.D., et al. Feline leukaemia virus infection: age-related variation in response of cats to experimental infection. J Natl Cancer Inst 57 2 (1976) 365-369
70. Charreyre C., and Pedersen N.C. Study of feline leukaemia virus immunity. J Am Vet Med Assoc 199 10 (1991) 1316-1324
71. Lutz H., Pedersen N.C., Higgins J., et al. Humoral immune reactivity to feline leukaemia virus and associated antigens in cats naturally infected with feline leukaemia virus. Cancer Res 40 (1980) 3642-3651
72. Hebebrand L.C., Mathes L.E., and Olsen R.G. Inhibition of concanavalin A stimulation of feline lymphocytes by inactivated feline leukaemia virus. Cancer Res 37 (1977) 4532-4533
73. Hebebrand L.C., Olsen R.G., Mathes L.E., et al. Inhibition of human lymphocyte mitogen and antigen response by a 15,000-dalton protein from feline leukaemia virus. Cancer Res 39 (1979) 443-447
74. Mathes L.E., Olsen R.G., Hebebrand L.C., et al. Abrogation of lymphocyte blastogenesis by a feline leukaemia virus protein. Nature 274 (1978) 687-689
75. Perryman L.E., Hoover E.A., and Yohn D.S. Immunologic reactivity of the cat: immunosuppression in experimental feline leukaemia. J Natl Cancer Inst 49 (1972) 1357-1365
76. Cockerell G.L., Hoover E.A., Krakowka S., et al. Lymphocyte mitogen reactivity and enumeration of circulating B- and T- cells during feline leukaemia virus infection in the cat. J Natl Cancer Inst 57 5 (1976) 1095-1099
77. Trainin Z., Wernicke D., Ungar-Waron H., et al. Suppression of the humoral antibody response in natural antibody response in natural retrovirus infections. Science 220 (1983) 858-859
78. Lafrado L.J., and Olsen R.G. Demonstration of depressed polymorphonuclear leukocyte function in nonviraemic FeLV-infected cats. Cancer Invest 4 4 (1986) 297-300
79. Copelan E.A., Rinehart J.J., Lewis M., et al. The mechanism of retrovirus suppression of human T cell proliferation in vitro. J Immunol 131 4 (1983) 2017-2020
80. Mathes L.E., Olsen R.G., Hebebrand L.C., et al. Immunosuppressive properties of a virion polypeptide, a 15,000-dalton protein, from feline leukaemia virus. Cancer Res 39 (1979) 950-955
81. Lafrado L.J., Lewis M.G., Mathes L.E., et al. Suppression of in vitro neutrophil function by feline leukaemia virus (FeLV) and purified FeLV-p15E. J Gen Virol 68 (1987) 507-513
82. Orosz C.G., Zinn N.E., Olsen R.G., et al. Retrovirus-mediated immunosuppression. II. FeLV-UV alters in vitro murine T lymphocyte behaviour by reversibly impairing lymphokine secretion. J Immunol 135 1 (1985) 583-590
83. Liu W.T., Good R.A., Trang L.Q., et al. Remission of leukaemia and loss of feline leukaemia virus in cats injected with Staphylococcus protein A: association with increased circulating interferon and complement-dependent cytotoxic antibody. Proc Natl Acad Sci U S A 81 (1984) 6471-6475
84. Engelman R.W., Fulton R.W., Good R.A., et al. Suppression of gamma interferon production by inactivated feline leukaemia virus. Science 227 (1984) 1368-1370
85. Muirden A. Prevalence of feline leukaemia virus and antibodies to feline immunodeficiency virus and feline coronavirus in stray cats sent to an RSPCA hospital. Vet Rec 150 20 (2002) 621-625
86. Hartmann K., Griessmayr P., Schulz B., et al. Quality of different in-clinic test systems for feline immunodeficiency virus and feline leukaemia virus infection. J Feline Med Surg 9 6 (2007) 439-445
87. Hardy W.D., Old L.J., Hess P.W., et al. Horizontal transmission of feline leukaemia virus. Nature 244 (1973) 266-269
88. Jarrett O. Overview of feline leukaemia virus research. J Am Vet Med Assoc 199 (1991) 1279-1281
89. Lutz H., Pedersen N.C., and Theilen G.H. Course of feline leukemia virus infection and its detection by enzyme-linked immunosorbent assay and monoclonal antibodies. Am J Vet Res 44 11 (1983) 2054-2059
90. Madewell B.R., and Jarrett O. Recovery of feline leukaemia virus from non-viraemic cats. Vet Rec 112 (1983) 339-342
91. Rojko J.L., Hoover E.A., Quackenbush S.L., et al. Reactivation of latent feline leukaemia virus infection. Nature 298 (1982) 385-388
92. Pacitti A.M., and Jarrett O. Duration of the latent state in feline leukaemia virus infections. Vet Rec 117 (1985) 472-474
93. Levy J.K., Crawford P.C., and Slater M.R. Effect of vaccination against feline immunodeficiency virus on results of serologic testing in cats. J Am Vet Med Assoc 225 10 (2004) 1558-1561
94. Bienzle D., Reggeti F., Wen X., et al. The variability of serological and molecular diagnosis of feline immunodeficiency virus infection. Can Vet J 45 9 (2004) 753-757
95. Steinrigl A., and Klein D. Phylogenetic analysis of feline immunodeficiency virus in Central Europe: a prerequisite for vaccination and molecular diagnostics. J Gen Virol 84 Pt 5 (2003) 1301-1307
96. Kusuhara H., Hohdatsu T., Seta T., et al. Serological differentiation of FIV-infected cats from dual-subtype feline immunodeficiency virus vaccine (Fel-O-Vax FIV) inoculated cats. Vet Microbiol 120 3-4 (2007) 217-225
97. MacDonald K., Levy J.K., Tucker S.J., et al. Effects of passive transfer of immunity on results of diagnostic tests for antibodies against feline immunodeficiency virus in kittens born to vaccinated queens. J Am Vet Med Assoc 225 10 (2004) 1554-1557
98. Jarrett O., and Ganière J.-P. Comparative studies of the efficacy of a recombinant feline leukaemia virus vaccine. Vet Rec 138 (1996) 7-11
99. Sparkes H. Feline leukaemia virus: a review of immunity and vaccination. J Small Anim Pract 38 (1997) 187-194
100. Kirpensteijn J. Feline injection site-associated sarcoma: is it a reason to critically evaluate our vaccination policies?. Vet Microbiol 117 1 (2006) 59-65
101. Hardy W.D., Hess P.W., MacEwan G., et al. Biology of feline leukaemia virus in the natural environment. Cancer Res 36 (1976) 582-588
102. Torres A.N., Mathiason C.K., and Hoover E.A. Re-examination of feline leukemia virus: host relationships using real-time PCR. Virology 332 1 (2005) 272-283
103. Tandon R., Cattori V., Willi B., et al. Copy number polymorphism of endogenous feline leukemia virus-like sequences. Mol Cell Probes 21 4 (2007) 257-266
104. Klenerman P., Hengartner H., and Zinkernagel R.M. A non-retroviral RNA virus persists in DNA form. Nature 390 (1997) 298-301
105. Pedersen N.C. Immunogenicity and efficacy of a commercial feline leukemia virus vaccine. J Vet Intern Med 7 (1993) 34-39
106. Hawks D.M., Legendre A.M., Rohrbach B.W., et al. Antibody response of kittens after vaccination followed by exposure to feline leukaemia virus-infected cats. J Am Vet Med Assoc 199 10 (1991) 1463-1469
107. Jelinek F. Postinflammatory sarcoma in cats. Exp Toxicol Pathol 55 (2003) 167-172
108. Kass P.H., Spangler W.L., Hendrick M.J., et al. Multicenter case-control study of risk factors associated with development of vaccine-associated sarcomas in cats. J Am Vet Med Assoc 223 9 (2003) 1283-1292
109. Gobar G.M., and Kass P.H. World Wide Web-based survey of vaccination practices, postvaccinal reactions, and vaccine site-associated sarcomas in cats. J Am Vet Med Assoc 220 10 (2002) 1477-1482
110. Osterhaus A., Weijer K., Uytdehaag F., et al. Induction of protective immune response in cats by vaccination with feline leukemia virus iscom. J Immunol 135 (1985) 591-596
111. Willemse M.J., van Schooneveld S.H., Chalmers W.S., et al. Vaccination against feline leukaemia using a new feline herpesvirus type 1 vector. Vaccine 14 (1996) 1511-1516
112. Boyer J.D., Ugen K.E., Chattergoon M., et al. DNA vaccination as anti-human immunodeficiency virus immunotherapy in infected chimpanzees. J Infect Dis 176 6 (1997) 1501-1509
113. Fuller D.H., Corb M.M., Barnett S., et al. Enhancement of immunodeficiency virus-specific immune responses in DNA-immunized rhesus macaques. Vaccine 15 8 (1997) 924-926
114. Hosie M.J., Flynn J.N., Rigby M.A., et al. DNA vaccination affords significant protection against feline immunodeficiency virus infection without inducing detectable antiviral antibodies. J Virol 72 9 (1998) 7310-7319
115. Donnelly J.J., Wahren B., and Liu M.A. DNA vaccines: progress and challenges. J Immunol 175 2 (2005) 633-639
116. Cohen A., Boyer J.D., and Weiner D.B. Modulating the immune response to genetic immunization. FASEB J 12 15 (1998) 1611-1626
117. Lee A.H., Suk Suh Y., and Chul Sung Y. DNA inoculations with HIV-1 recombinant genomes that express cytokine genes enhance HIV-1 specific immune responses. Vaccine 17 5 (1999) 473-479
118. Calarota S.A., and Weiner D.B. Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants. Immunol Rev 199 1 (2004) 84-99
119. O'Donovan L.H., McMonagle E.L., Taylor S., et al. A vector expressing feline mature IL-18 fused to IL-1[beta] antagonist protein signal sequence is an effective adjuvant to a DNA vaccine for feline leukaemia virus. Vaccine 23 29 (2005) 3814-3823
120. Dunham S.P. Lessons from the cat: development of vaccines against lentiviruses. Vet Immunol Immunopathol 112 1-2 (2006) 67-77
121. Uhl E.W., Heaton-Jones T.G., Pu R., et al. FIV vaccine development and its importance to veterinary and human medicine: a review FIV vaccine 2002 update and review. Vet Immunol Immunopathol 90 3-4 (2002) 113-132
122. Dunham S.P., and Jarrett O. FIV as a model for AIDS vaccine studies. In: Friedman H., Specter S., and Bendinelli M. (Eds). In vivo models of HIV disease and control (2006), Springer, New York 293-332
123. Hosie M.J., and Beatty J.A. Vaccine protection against feline immunodeficiency virus: setting the challenge. Aust Vet J 85 1-2 (2007) 5-12
124. Pu R., Coleman J., Omori M., et al. Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates. AIDS 15 10 (2001) 1225-1237
125. Kusuhara H., Hohdatsu T., Okumura M., et al. Dual-subtype vaccine (Fel-O-Vax FIV) protects cats against contact challenge with heterologous subtype B FIV infected cats. Vet Microbiol 108 3-4 (2005) 155-165
126. Pu R., Coleman J., Coisman J., et al. Dual-subtype FIV vaccine (Fel-O-Vax FIV) protection against a heterologous subtype B FIV isolate. J Feline Med Surg 7 1 (2005) 65-70
127. Dunham S.P., Bruce J., MacKay S., et al. Limited efficacy of an inactivated feline immunodeficiency virus vaccine. Vet Rec 158 16 (2006) 561-562
128. Phadke A.P., Concha-Bermejillo A., Wolf A.M., et al. Pathogenesis of a Texas feline immunodeficiency virus isolate: an emerging subtype of clade B. Vet Microbiol 115 1-3 (2006) 64-76
129. Weaver E.A., Collisson E.W., Slater M., et al. Phylogenetic analyses of Texas isolates indicate an evolving subtype of the clade B feline immunodeficiency viruses. J Virol 78 4 (2004) 2158-2163
130. Este J.A., and Telenti A. HIV entry inhibitors. Lancet 370 9581 (2007) 81-88
131. Suzuki Y., and Craigie R. The road to chromatin-nuclear entry of retroviruses. Nat Rev Microbiol 5 3 (2007) 187-196
132. De Clercq E. HIV-chemotherapy and -prophylaxis: new drugs, leads and approaches. Int J Biochem Cell Biol 36 9 (2004) 1800-1822
133. Brazil M. HIV-1. Viral assembly inhibitors on the horizon. Nat Rev Drug Discov 4 9 (2005) 716-717
134. Balzarini J. Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy. Nat Rev Microbiol 5 8 (2007) 583-597
135. de Fougerolles A., Vornlocher H.P., Maraganore J., et al. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 6 6 (2007) 443-453
136. Ketzinel-Gilad M., Shaul Y., and Galun E. RNA interference for antiviral therapy. J Gene Med 8 8 (2006) 933-950
137. Hartmann K., Donath A., Beer B., et al. Use of two virustatica (AZT, PMEA) in the treatment of FIV and of FeLV seropositive cats with clinical symptoms. Vet Immunol Immunopathol 35 1-2 (1992) 167-175
138. Egberink H.F., Hartman K., and Horzinek M.C. Chemotherapy of feline immunodeficiency virus infection. J Am Vet Med Assoc 199 10 (1991) 1485-1487